Merck & Co.’s Keytruda Gets Fighting Chance In TNBC
Successful KEYNOTE-522 Results May Sway FDA
Executive Summary
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.
You may also be interested in...
Keytruda TNBC Approval Now More Likely, But Data Is Bad News For pCR Surrogate Endpoint
Merck unveiled event-free survival results for Keytruda in triple-negative breast cancer following failure earlier this year to gain approval on a surrogate endpoint.
Keytruda To Enjoy First-To-Market Advantage As TNBC Approval Now More Likely
Merck & Co. unveiled event-free survival data for Keytruda in triple-negative breast cancer, following a failure earlier this year to gain approval on a surrogate endpoint.
Keytruda Adjuvant Kidney Cancer Data Cement The Future Of IO
The data illustrate the growing importance of adjuvant settings of solid tumors for PD-1/PD-L1 inhibitors, which could make up more than one-quarter of their sales in 2025.